Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2026
Regulatory Filings Classification · 82% confidence The document is a regulatory announcement disclosing Sanofi’s total number of shares and voting rights under French commercial code and AMF regulations. It does not present meeting results, vote outcomes, or constitute a financial report; rather it is a compliance filing. No specific category matches exactly, so it falls under the fallback “Regulatory Filings” (RNS).
2026-05-19 French
Sanofi: Information concerning the total number of voting rights and shares - April 2026
Regulatory Filings Classification · 82% confidence The document is a statutory announcement under French Commercial Code and AMF rules providing the total number of shares and voting rights as of a certain date. It is neither a full financial report nor a vote result, nor a threshold‐crossing shareholding notice. It is a regulatory disclosure of share and voting‐rights structure, thus best classified as a general regulatory filing (RNS).
2026-05-19 English
Communiqué de presse : ATS : Les données de phase 2 démontrent la supériorité de l'efdoralprin alfa par rapport au traitement de substitution standard pour atteindre des taux de fAAT plus élevés dans
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi dated May 18, 2026, presenting clinical trial phase 2 data for a drug candidate (efdoralprin alfa) for alpha-1 antitrypsin deficiency (DAAT). It discusses study results, safety data, and regulatory designations such as Fast Track and orphan drug status. The document is a detailed announcement of clinical trial results and regulatory status, not a financial report, earnings release, or management discussion. It is not a regulatory filing or certification. It is not an investor presentation or annual/interim report. It is a press release focused on clinical data and regulatory updates. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit other specific categories.
2026-05-18 French
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
Capital/Financing Update Classification · 95% confidence The document is a press release announcing phase 2 clinical trial data for a drug candidate (efdoralprin alfa) by Sanofi. It includes detailed study results, safety data, and forward-looking statements. It is not a financial report, regulatory filing, or management discussion. It is a corporate announcement focused on clinical trial outcomes and product development progress, typical of a Capital/Financing Update or product development update. There is no indication of financial statements, earnings data, or regulatory certifications. The document length is over 13,000 characters, so it is not a brief announcement or report publication notice. The content aligns best with a Capital/Financing Update (CAP) as it relates to clinical development progress and potential impact on company valuation and financing.
2026-05-18 English
6-K - Sanofi (0001121404) (Filer)
Regulatory Filings
2026-05-05 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 90% confidence The document is titled “Déclaration des transactions sur actions propres” by Sanofi, detailing share repurchase transactions on its own shares over specific dates. This matches the definition for Transaction in Own Shares (Code: POS).
2026-04-29 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.